Group 1: Clinical Trial Results - Eli Lilly's TOGETHER-PsO trial showed that 27.1% of participants receiving Taltz and Zepbound achieved complete skin clearance and at least 10% weight loss, compared to 5.8% for Taltz alone, meeting the primary endpoint [2] - The combination of Taltz and Zepbound resulted in a 40% relative increase in the proportion of patients achieving PASI 100 compared to Taltz monotherapy (40.6% vs. 29%) [2] Group 2: Licensing Agreement - CSL Limited entered into an exclusive licensing agreement with Eli Lilly for the development and commercialization of clazakizumab, with an upfront payment of $100 million and potential milestone payments and royalties on global net sales [4] - CSL retains exclusive rights to develop clazakizumab for preventing cardiovascular events in patients with end-stage kidney disease, while Lilly will explore additional indications [5] Group 3: Stock Performance - The stock is currently trading 2.7% below its 20-day simple moving average and 3.2% below its 50-day simple moving average, indicating short-term weakness, but remains 4.3% above its 100-day simple moving average and 17.6% above its 200-day simple moving average, suggesting longer-term strength [7] - The RSI is at 48.22, indicating neutral territory, while the MACD shows bearish pressure with a value of -5.0984 below its signal line of -3.9365 [8]

FDA Designation - The FDA granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro as a monotherapy for adults with advanced head and neck squamous cell carcinoma [1] - The designation is for patients with recurrent or metastatic cancer that is HPV-unrelated after progression on platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [2] - Rybrevant Faspro is also approved for multiple settings in locally advanced or metastatic non-small cell lung cancer and is being evaluated in additional solid tumors, including colorectal cancer [2] Clinical Studies - The Breakthrough Therapy Designation is supported by data from the open-label Phase 1b/2 OrigAMI-4 study, which showed promising clinical activity with rapid and durable responses in a heavily pretreated patient population [3] - Subcutaneous amivantamab is being further evaluated in the ongoing Phase 3 OrigAMI-5 study, assessing its combination with Merck's Keytruda and carboplatin versus 5-fluorouracil plus pembrolizumab and platinum-based chemotherapy for HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma [4] New Dosing Schedule - The FDA approved a new, simplified monthly dosing schedule for Rybrevant Faspro in combination with oral Lazcluze for the first-line treatment of EGFR-mutated advanced non-small cell lung cancer [5] Contract Extension - Trellus Health plc extended its contract with Johnson & Johnson's Health Care Systems unit for six months to continue providing Trellus Elevate for patients with moderate to severely active inflammatory bowel disease [6] - The extension was influenced by the achievement of engagement and satisfaction metrics during the initial pilot phase [6]

Core Viewpoint - Pfizer offers a unique combination of scale, stability, and a 6% dividend yield, which is rare among large-cap companies, suggesting a potential investment opportunity [1] Group 1: Financial Performance - Pfizer has steady cash flow, which supports its dividend yield and overall financial health [1] - The company is currently valued modestly, indicating potential for growth and investment upside [1] Group 2: Market Position - As a defensive giant, Pfizer may be positioning itself for a rebound in the market, making it an attractive option for income-focused investors [1] - Analysts suggest that there is upside potential for Pfizer, which could enhance its appeal as a value play [1]

Core Insights - Johnson & Johnson announced long-term data from the QUASAR study showing that TREMFYA® (guselkumab) maintains clinical and endoscopic remission in ulcerative colitis patients over three years, with over 80% of patients in clinical remission and more than 50% in endoscopic remission at Week 140 [1][2]. Group 1: Clinical Efficacy - At Week 140, 80.8% of patients treated with TREMFYA® were in clinical remission, while 53.6% achieved endoscopic remission [1]. - 78.6% of patients experienced histo-endoscopic mucosal improvement (HEMI), indicating significant intestinal healing [1]. - Among those in clinical remission at Week 44, 87.5% maintained remission through Week 140, demonstrating sustained efficacy [1]. Group 2: Study Retention and Safety - Approximately 89% of eligible study participants completed treatment through Week 140, indicating high retention rates [1]. - No new safety concerns were reported during the study, reinforcing the long-term safety profile of TREMFYA® [1][2]. Group 3: Mechanism and Approval - TREMFYA® is the first and only approved dual-acting monoclonal antibody that blocks IL-23 and binds to CD64, targeting immune-mediated diseases [1][2]. - The drug has received FDA and European Commission approval for treating both moderately to severely active Crohn's disease and ulcerative colitis [1][2]. Group 4: Additional Research and Commitment - Johnson & Johnson presented 30 abstracts at the European Crohn's and Colitis Organisation (ECCO) 2026 conference, highlighting ongoing research and commitment to inflammatory bowel disease treatments [1]. - Two other abstracts from Johnson & Johnson were recognized as Top 10 oral abstracts, showcasing the company's dedication to advancing treatment options [1].

The S&P 500 entered the third year of a bull market back in October and finished the year with a bang: a double-digit gain that brought the index's three-year increase to 78%. Over that time period, investors have been particularly optimistic about stocks in high-growth areas, from artificial intelligence and quantum computing to companies leading in the weight loss drug market. In this context, stocks including AI leader Nvidia, quantum innovator IonQ, and weight loss drug giant Eli Lilly each have skyroc ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 6, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements since 2013 [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx's management provided misleading information regarding the efficacy of setrusumab (UX 143) in clinical trials for Osteogenesis Imperfecta, leading to inflated stock prices [5][6]. - It is claimed that while setrusumab increased bone density, it did not correlate with a decrease in fracture rates, contrary to management's assertions [6].

Core Viewpoint - Vanda Pharmaceuticals Inc. (VNDA) shares surged over 40% in after-hours trading following FDA approval of BYSANTI, a new treatment for bipolar I disorder and schizophrenia in adults [1] Group 1: Product Approval and Market Impact - The FDA has approved BYSANTI as a first-line therapy for acute treatment of manic or mixed episodes associated with bipolar I disorder and for schizophrenia in adults [1] - BYSANTI is expected to be commercially available in the third quarter of this year [1] - Following the approval, VNDA shares closed at $5.76, down 5.57% during regular trading, but rose to $8.30 in after-hours trading [3] Group 2: Intellectual Property and Future Developments - BYSANTI will be protected by regulatory data exclusivity and U.S. patents, with the last patent expiring in 2044, which supports long-term innovation and patient benefits [2] - This approval marks the second new drug for Vanda in less than two months, following the approval of NEREUS for motion-induced vomiting in December 2025 [3] - A phase 3 trial for BYSANTI as a once-daily adjunctive treatment for major depressive disorder (MDD) is currently underway, with results expected this year [3] Group 3: Stock Performance - VNDA has traded between $3.81 and $9.60 over the past year [3]

Core Viewpoint - The Corcept class action lawsuit alleges that Corcept Therapeutics and its executives misrepresented the status of their New Drug Application (NDA) for relacorilant, leading to significant financial losses for investors when the FDA issued a Complete Response Letter (CRL) indicating concerns about the clinical evidence supporting the NDA [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit seeks to represent purchasers of Corcept common stock from October 31, 2024, to December 30, 2025 [1]. - The lawsuit is titled Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated and is filed in the Northern District of California [1]. - The allegations include that Corcept misled investors about the FDA's review process and the adequacy of clinical evidence for relacorilant [3][4]. Group 2: FDA Concerns - The FDA had raised concerns about the clinical evidence supporting the NDA for relacorilant, indicating a material risk of non-approval [3]. - On December 31, 2025, Corcept disclosed that the FDA issued a CRL, stating it could not make a favorable benefit-risk assessment without additional evidence [4]. - A redacted copy of the CRL published on January 30, 2026, detailed the FDA's concerns regarding the sufficiency of the clinical studies submitted [5]. Group 3: Legal Process - Investors who suffered losses during the class period can seek to be appointed as lead plaintiff in the lawsuit [6]. - The lead plaintiff will represent the interests of all class members and can select a law firm for litigation [6]. Group 4: Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [7]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history [7].

Core Insights - Novo Nordisk has faced challenges, including disappointing fourth-quarter results and negative guidance for fiscal year 2026, leading to a nearly 15% drop in stock price [1][7] - The launch of an oral version of Wegovy is a significant development for Novo Nordisk, as it expands the market rather than cannibalizing existing sales [2][5] Company Performance - Novo Nordisk's stock price has recently declined, with a current price of $47.45 and a market cap of $163 billion [6][7] - The company has a gross margin of 80.90% and a dividend yield of 3.56% [7] Product Development - Oral Wegovy is gaining traction, with increasing prescription volumes and the potential to attract new patients [4][5] - The company is awaiting approval for CagriSema, a next-generation weight loss and diabetes therapy, which could positively impact future sales [8][9] Competitive Landscape - Eli Lilly's success with Oral Wegovy indicates a competitive market, as it prepares to launch its own oral GLP-1 therapy, orforglipron [7][8] - Despite the positive reception of Oral Wegovy, Novo Nordisk anticipates a decline in sales due to competition and government-led drug price negotiations [7][8]

Core Viewpoint - A class action lawsuit has been filed on behalf of investors who purchased Corcept Therapeutics common stock between October 31, 2024, and December 30, 2025, indicating potential legal challenges for the company [1]. Company Overview - Corcept Therapeutics is a pharmaceutical company focused on developing medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol [1].